Literature DB >> 10829448

[Renal cell carcinoma in patient with situs inversus and Kartagener syndrome].

A Jiménez Verdejo1, J L Martínez Torres, F Palao Yago, J Tinaut Ranera, M Arrabal Martín, J L Miján Ortiz, A Zuluaga Gómez.   

Abstract

A case of a adenocarcinoma renal in a patient with situs inversus complete to which was associated bronchiectasis and chronic sinusitis (kartagener's syndrome) is reported. It is the third case described in the international literature of a renal cells carcinoma in a patient with situs inversus totalis and the first in patient the one which has the triada classic of the kartagener's syndrome plus sterility. The tumor was discovered in a way incidental upon accomplishing a TAC toracoabdominal and was solved through nefrectomia for lumbotomy approach.

Entities:  

Mesh:

Year:  2000        PMID: 10829448     DOI: 10.1016/s0210-4806(00)72424-7

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  4 in total

1.  A case of renal cell carcinoma in a patient with situs inversus: Operative considerations and a review of the literature.

Authors:  Justin Oake; Darrel Drachenberg
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

2.  Founder mutation(s) in the RSPH9 gene leading to primary ciliary dyskinesia in two inbred Bedouin families.

Authors:  Orit Reish; Montgomery Slatkin; Daphne Chapman-Shimshoni; Arnon Elizur; Barry Chioza; Victoria Castleman; Hannah M Mitchison
Journal:  Ann Hum Genet       Date:  2010-01-08       Impact factor: 1.670

3.  Renal Carcinoma and Kartagener Syndrome: An Unusual Association.

Authors:  Hamza Dergamoun; Abdelilah El Alaoui; Imad Boualaoui; Hachem Sayegh; Lounis Benslimane; Yassine Nouini
Journal:  Case Rep Urol       Date:  2020-05-16

Review 4.  Management of primary ciliary dyskinesia/Kartagener's syndrome in infertile male patients and current progress in defining the underlying genetic mechanism.

Authors:  Yan-Wei Sha; Lu Ding; Ping Li
Journal:  Asian J Androl       Date:  2014 Jan-Feb       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.